The European Commission has granted marketing authorization for Emcitate (tiratricol), making it the first approved treatment for monocarboxylate transporter 8 (MCT8) deficiency in the EU.
Egetis Therapeutics will investigate tiratricol (Emcitate®) for Resistance to Thyroid Hormone beta (RTHβ), a rare genetic disorder with no approved treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.